Download the app
App StorePlay Store
Beige
Login
← All tags

eli lilly

Eli Lilly launches Lormalzi in India targeting Alzheimer’s amyloid plaques with disease modifying promise

Eli Lilly launches Lormalzi in India targeting Alzheimer’s amyloid plaques with disease modifying promise

Eli Lilly is expanding its India specialty pipeline by making Alzheimer’s disease a central bet, alongside obesity and metabolic therapies. The company launched Lormalzi (donanemab), a once-monthly intravenous treatment aimed at amyloid plaques driving early symptomatic Alzheimer’s, unlike older drugs that mainly ease symptoms. Lormalzi is priced at Rs 91,688 per 350 mg vial, delivered every four weeks for up to 18 months, and will roll out through hospitals and pharmacies with an alternative access program. Lilly also cites diagnosis delays, expecting blood-based biomarkers to help.

Summarised by Beize from a story on The Economic Times on 14 May 2026
Eli Lilly launches monthly Alzheimer drug Lormalzi in India at ₹91,688 per vial

Eli Lilly launches monthly Alzheimer drug Lormalzi in India at ₹91,688 per vial

Eli Lilly has launched Lormalzi, a monthly treatment for early Alzheimer’s disease, in India. The therapy targets amyloid plaques and is set to be available this month. Positioned as part of the company’s broader push in specialty medicines, Lormalzi comes with a steep price tag of ₹91,688 per vial. The move signals rising focus on Alzheimer’s innovation in India.

Summarised by Beize from a story on The Economic Times on 13 May 2026

Your news, in seconds

App StorePlay Store
Eli Lilly pauses India obesity campaign after regulator warning and seeks clearer promotion rules

Eli Lilly pauses India obesity campaign after regulator warning and seeks clearer promotion rules

Eli Lilly has paused its obesity awareness campaign in India after the country’s drug regulator cautioned it over potential rule violations. The initiative sought to reframe obesity as a chronic disease using multiple media formats without naming specific products. Lilly says regulatory uncertainty and conflicting guidance led to the halt, while the regulator warned against indirect promotion of medicines.

Summarised by Beize from a story on The Economic Times on 12 May 2026
Novo Nordisk relaunches diabetes pills as Ozempic to win market share from Eli Lilly

Novo Nordisk relaunches diabetes pills as Ozempic to win market share from Eli Lilly

Novo Nordisk is relaunching a diabetes tablet in the United States under the Ozempic name, starting with select adult doses this Monday. The strategy banks on Ozempic’s blockbuster brand recognition to lift sales and help Novo regain market share from rival Eli Lilly as competition intensifies in diabetes care.

Summarised by Beize from a story on The Economic Times on 1 May 2026
Eli Lilly lifts forecasts as oral GLP 1 pill and Zepbound drive results

Eli Lilly lifts forecasts as oral GLP 1 pill and Zepbound drive results

Eli Lilly raised its annual profit and revenue outlook after a stronger-than-expected first quarter, powered by steady demand for its GLP-1 therapies. Results followed the company’s initial reporting since launching its oral GLP-1 pill, Foundayo, with continued momentum for weight-loss and diabetes brands Zepbound and Mounjaro.

Summarised by Beize from a story on The Economic Times on 30 Apr 2026
Eli Lilly to buy Ajax Therapeutics for up to 2.3 billion to push new oral myelofibrosis drug

Eli Lilly to buy Ajax Therapeutics for up to 2.3 billion to push new oral myelofibrosis drug

Eli Lilly plans to acquire Ajax Therapeutics for up to $2.3 billion to develop a potential new oral treatment for myelofibrosis, a rare blood cancer. The company expects key clinical data in 2026 and intends to rapidly advance the program into larger trials, aiming to add another targeted option for patients and specialists.

Summarised by Beize from a story on The Economic Times on 27 Apr 2026

Never miss a story

App StorePlay Store
Eli Lilly responds after Gurugram bust of counterfeit Mounjaro made from China supplies

Eli Lilly responds after Gurugram bust of counterfeit Mounjaro made from China supplies

Gurugram law enforcement has reportedly dismantled a counterfeit Mounjaro operation, placing two people in custody. Authorities say the ring imported raw materials from China and manufactured the injections at a private home, supplying illicit diabetes and obesity drugs. Eli Lilly issued a statement after the Gurugram drug racket was exposed, underscoring growing concerns about counterfeit GLP-1 medications.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play